hif1an Antibody

What is HIF1AN and what is its functional significance in cellular pathways?

HIF1AN, also known as Factor Inhibiting HIF-1 (FIH-1), functions as a negative regulator of the hypoxia-inducible factor (HIF) pathway. It plays a crucial role in regulating cellular responses to hypoxic conditions by hydroxylating an asparagine residue in the C-terminal transactivation domain of HIF-1α. This hydroxylation prevents the interaction of HIF-1α with transcriptional coactivators, thereby inhibiting the transcriptional activity of the HIF complex. Through this mechanism, HIF1AN influences various cellular processes including metabolism, angiogenesis, and apoptosis. Dysregulation of HIF1AN has been implicated in various pathological conditions including cancer, cardiovascular disorders, and neurodegenerative diseases, making it a significant target for therapeutic investigation .

The protein has a molecular weight of approximately 40-42 kDa and is detectable in various cell lines including human glioblastoma (A172), mouse myoblast (C2C12), and human cervical epithelial carcinoma (HeLa) cell lines . Understanding HIF1AN's function provides crucial insights into oxygen-sensing mechanisms and cellular adaptation to hypoxia, essential knowledge for research in oncology, cardiovascular biology, and regenerative medicine.

What are the key differences between HIF1AN (FIH-1) antibodies and HIF-1α antibodies?

While these proteins function within the same pathway, their antibodies target distinct molecules with different cellular functions, expression patterns, and molecular characteristics:

HIF1AN antibodies detect the regulatory enzyme that modifies HIF-1α, while HIF-1α antibodies detect the transcription factor itself. In experimental design, HIF1AN antibodies show consistent detection regardless of oxygen conditions, whereas HIF-1α antibodies typically require hypoxic conditions or chemical inducers like desferroxamine (DFO) for robust detection . These fundamental differences dictate appropriate experimental controls and interpretation of results when studying the hypoxia response pathway.

What validation methods should be employed to confirm HIF1AN antibody specificity?

Rigorous validation is critical to ensure experimental reproducibility and accurate interpretation of results. For HIF1AN antibodies, a comprehensive validation approach should include:

• Knockout (KO) validation: Testing antibodies against HIF1AN knockout cell lines represents the gold standard for specificity confirmation. Western blot analysis comparing parental and HIF1AN-KO cell lines should show absence of the target band (~40-42 kDa) in the knockout line, as demonstrated with HIF-1α antibodies in the search results .

• Multiple detection methods: Cross-validation using different techniques such as Western blot, immunocytochemistry, and Simple Western™ to confirm consistent detection patterns .

• Species cross-reactivity assessment: Testing the antibody across multiple species when working with animal models. The antibodies in the search results demonstrate reactivity with human, mouse, and rat samples, which should be verified with appropriate positive controls .

• Molecular weight verification: Confirming that the detected protein appears at the expected molecular weight (~40-42 kDa for HIF1AN) under reducing conditions .

• Blocking peptide competition: Performing assays with and without competing peptides containing the immunogen sequence to demonstrate binding specificity .

Comprehensive validation increases confidence in experimental findings and prevents misinterpretation of results due to non-specific binding or cross-reactivity with unintended targets.

What are the optimal conditions for detecting HIF1AN in different cellular compartments?

HIF1AN exhibits both cytoplasmic and nuclear localization, with distribution patterns that may vary by cell type and physiological condition. Optimizing detection requires consideration of several factors:

For immunocytochemistry/immunofluorescence detection:

• Fixation method: Paraformaldehyde (4%) demonstrates optimal preservation of HIF1AN epitopes while maintaining cellular architecture.

• Permeabilization: Use 0.1-0.3% Triton X-100 for balanced access to both nuclear and cytoplasmic compartments.

• Antibody concentration: For the antibodies described in the search results, optimal dilutions range from 3-25 μg/mL depending on the specific antibody and cell type .

• Incubation conditions: Room temperature incubation for 3 hours has been demonstrated to be effective for several cell lines including A172 human glioblastoma and C2C12 mouse myoblast cell lines .

• Counterstaining: DAPI counterstaining enables clear visualization of nuclear localization.

The fluorescent ICC staining results in search result demonstrated that HIF1AN shows distinct subcellular localization patterns: in A172 human glioblastoma cells, staining was observed in both cytoplasm and nuclei, while in C2C12 mouse myoblast cells, staining was predominantly cytoplasmic . This contrasts with HIF-1α, which shows strong nuclear localization specifically after hypoxic stimulation or treatment with hypoxia mimetics such as DFO .

These differences in localization patterns provide important insights into the functional relationship between HIF1AN and HIF-1α in the cellular hypoxic response pathway.

How should researchers design experiments to investigate HIF1AN-HIF-1α interaction dynamics?

Investigating the dynamic interplay between HIF1AN and HIF-1α requires carefully designed experiments that capture their regulatory relationship under varying oxygen conditions. A comprehensive experimental design should include:

• Time-course analysis: Monitor both proteins across multiple timepoints (0-24 hours) after hypoxic stimulation or treatment with hypoxia mimetics like DFO or cobalt chloride to capture the temporal dynamics of their interaction.

• Oxygen gradient experiments: Rather than just normoxia vs. hypoxia, establish multiple oxygen tensions (21%, 5%, 1%, and 0.1% O₂) to understand the threshold effects on HIF1AN activity and HIF-1α stabilization.

• Co-immunoprecipitation (Co-IP): Use antibodies against HIF1AN to pull down protein complexes and probe for HIF-1α, or vice versa, to directly assess physical interactions under different conditions.

• Proximity ligation assay (PLA): This technique can visualize protein-protein interactions in situ with high sensitivity, providing spatial information about where in the cell HIF1AN and HIF-1α interact.

• Pharmacological manipulation: Use proteasome inhibitors (e.g., MG132) alongside hypoxia mimetics to distinguish between hydroxylation-dependent and independent regulatory mechanisms .

• Dual immunofluorescence: Co-stain for both HIF1AN and HIF-1α to visualize their relative localization patterns under different conditions using confocal microscopy.

The search results show that HIF-1α protein accumulation can be regulated by various treatments, including sulforaphane (SFN), which inhibits HIF-1α accumulation without altering mRNA levels, suggesting post-translational regulation . Similar approaches could be applied to study HIF1AN-mediated regulation of HIF-1α.

What are the critical considerations for quantitative analysis of HIF1AN expression in Western blot?

Quantitative Western blot analysis of HIF1AN requires attention to several methodological details to ensure accurate and reproducible results:

• Sample preparation: Total cell lysates should be prepared using buffer systems containing protease inhibitors. The search results indicate successful detection using Immunoblot Buffer Group 1 under reducing conditions .

• Loading controls: GAPDH (36-38 kDa) serves as an appropriate loading control as demonstrated in the knockout validation experiments . Alternative loading controls include β-actin or α-tubulin, ensuring minimal molecular weight overlap with HIF1AN.

• Antibody concentration optimization: Based on the search results, effective concentrations for Western blot detection range from 0.25-2 μg/mL depending on the specific antibody . Concentration optimization should be performed for each new cell line or tissue.

• Normalization strategies: For comparative studies examining HIF1AN across different conditions:

  • Normalize to loading controls

  • Include a common reference sample across multiple blots

  • Consider internal normalization controls specific to your experimental system

• Dynamic range considerations: When expecting substantial changes in expression, perform serial dilutions to ensure measurements remain within the linear detection range of the imaging system.

• Membrane selection: PVDF membranes have been successfully used for HIF1AN detection as documented in the search results .

• Chemiluminescence detection optimization: Exposure times should be optimized to avoid saturation while maintaining sensitivity.

For detection of HIF1AN across multiple species, the search results indicate successful visualization of a specific band at approximately 40-42 kDa in human glioblastoma (A172) and mouse myoblast (C2C12) cell lines using Mouse Anti-Human/Mouse FIH-1/HIF-1AN Monoclonal Antibody .

How do different chemical inducers of hypoxia affect HIF1AN detection and function?

The search results demonstrate that treatment with DFO or cobalt chloride significantly increases HIF-1α detection in Western blot and immunofluorescence applications . These treatments have been used at concentrations of 1 mM DFO overnight or 250 μM cobalt chloride for 4 hours .

When designing experiments using these chemical inducers, researchers should consider:

• The distinct mechanisms of each agent and potential off-target effects

• Appropriate positive and negative controls

• Time-dependent effects, as prolonged treatment may trigger adaptive responses

• Comparison with true hypoxia (1% O₂) to validate physiological relevance

The search results indicate that sulforaphane (SFN) can inhibit HIF-1α protein accumulation induced by these hypoxia mimetics, suggesting complex regulation of the pathway that may involve HIF1AN .

What approaches are recommended for multiplexing HIF1AN with other hypoxia pathway components?

Simultaneous detection of multiple hypoxia pathway components provides crucial insights into their coordinated regulation and relative expression levels. For effective multiplexing with HIF1AN:

• Antibody selection criteria for multiplexing:

  • Choose antibodies raised in different host species (e.g., rabbit anti-HIF1AN with mouse anti-HIF-1α)

  • Select antibodies targeting proteins with distinct molecular weights (HIF1AN: ~40-42 kDa; HIF-1α: ~110-120 kDa)

  • Verify minimal cross-reactivity between secondary detection systems

• Multicolor immunofluorescence optimization:

  • Use fluorophores with minimal spectral overlap (e.g., NorthernLights™ 557 as used in the search results )

  • Include single-color controls to assess bleed-through

  • Consider sequential rather than simultaneous antibody incubation for problematic combinations

  • Use appropriate counterstains like DAPI for nuclear visualization

• Western blot multiplexing strategies:

  • Sequential probing with stripping between antibodies (verify complete stripping)

  • Use differentially colored detection systems (e.g., near-infrared fluorescent secondaries)

  • Consider protein mass separation when detecting proteins of similar size

• Validation of multiplex protocols:

  • Compare results to single-plex detection to ensure sensitivity is not compromised

  • Include stimulation controls (e.g., DFO or hypoxia treatment) to verify expected response patterns

  • Perform knockout/knockdown controls to confirm specificity in multiplex settings

The search results describe successful detection of HIF-1α in conjunction with other proteins such as acetylated histone proteins (H3 and H4) and HDAC proteins following treatment with panobinostat and cisplatin . Similar approaches could be applied to study HIF1AN alongside these and other hypoxia pathway components.

What are common challenges in HIF1AN detection and how can they be resolved?

Researchers frequently encounter technical challenges when working with HIF1AN antibodies. Below are common issues and evidence-based solutions:

• Insufficient signal strength:

  • Increase antibody concentration (effective range in search results: 0.25-25 μg/mL depending on application)

  • Extend incubation time (3 hours at room temperature has been validated)

  • Optimize protein loading (0.2-0.5 mg/mL for Simple Western™)

  • Enhance signal development time or use more sensitive detection systems

• Background and non-specific binding:

  • Increase blocking stringency (5% BSA or milk in TBST)

  • Optimize antibody dilution to reduce non-specific binding

  • Include additional washing steps (at least 3×10 minutes with TBST)

  • Consider mouse IgG blocking reagents when working with mouse-derived antibodies on mouse tissues

• Inconsistent detection across cell types:

  • Adjust lysis conditions based on cellular compartmentalization

  • Optimize protein extraction protocols for different tissues

  • Validate antibody performance in each new cell type

  • Consider alternative antibody clones if persistent issues occur

• Multiplexing interference:

  • Sequential rather than simultaneous antibody incubation

  • Complete stripping verification when reprobing membranes

  • Species-specific secondary antibodies to minimize cross-reactivity

• Simple Western™ specific issues:

  • Non-specific interaction with the 230 kDa Simple Western standard may occur with some antibodies as noted in search result

  • Optimize separation system (12-230 kDa system has been validated)

  • Adjust loading concentration between 0.2-0.5 mg/mL as demonstrated effective in the search results

For each challenge, systematic optimization and appropriate controls are essential for developing robust, reproducible detection protocols.

What are the critical differences in protocols for detecting endogenous versus overexpressed HIF1AN?

Detection strategies must be tailored differently when working with endogenous versus overexpressed HIF1AN:

Endogenous HIF1AN Detection:

• Antibody selection: Polyclonal antibodies may offer better sensitivity for detecting native protein at endogenous levels .

• Sample preparation: Minimal processing helps preserve physiological interactions and modifications. The standard lysis buffers used in search results and are appropriate.

• Signal amplification: More sensitive detection systems may be required (ECL Prime or SuperSignal West Femto).

• Controls: Knockout or knockdown controls are essential to confirm specificity.

• Cell selection: Consider cell types with documented HIF1AN expression (A172, C2C12, HeLa as demonstrated in the search results) .

• Loading requirements: Higher protein loading (20-40 μg total protein) may be necessary.

Overexpressed HIF1AN Detection:

• Antibody selection: Both monoclonal and polyclonal antibodies work well with overexpressed systems due to abundant target.

• Sample preparation: More stringent lysis conditions can be used without compromising detection.

• Signal management: Reduce exposure times or antibody concentration to prevent signal saturation.

• Controls: Empty vector controls and expression verification are critical.

• Loading requirements: Reduce protein loading (5-10 μg total protein) to prevent oversaturation.

• Tag considerations: If using tagged constructs, compare detection with both tag-specific antibodies and HIF1AN antibodies.

The search results primarily focus on endogenous detection, with successful visualization in multiple cell lines under standard conditions. For recombinant protein detection, the Human/Mouse FIH-1/HIF-1AN Antibody was raised against E. coli-derived recombinant human FIH-1/HIF-1AN (Met1-Asn349), suggesting its utility for detecting overexpressed protein as well .

How can researchers optimize protocols for detecting HIF1AN in primary tissue samples versus cell lines?

Transitioning from cell lines to primary tissues introduces additional challenges that require protocol modifications:

Cell Line Protocols (as demonstrated in search results):

• Standard fixation with 4% paraformaldehyde for ICC

• Immersion fixation for adherent cells

• Straightforward permeabilization with 0.1-0.3% Triton X-100

• Consistent lysis protocols using standard buffers

• Relatively homogeneous populations simplifying interpretation

Primary Tissue Adaptations:

• Fixation optimization:

  • Perfusion fixation (for animal tissues) often provides superior morphology

  • Fixation time must be carefully optimized (typically 24-48 hours for larger specimens)

  • Consider alternative fixatives for specific applications (Bouin's for certain epitopes)

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

  • Enzymatic retrieval for certain tissues (proteinase K, trypsin)

  • Optimization for each tissue type is critical

• Background reduction strategies:

  • Endogenous peroxidase blocking (3% H₂O₂ in methanol for 10 minutes)

  • Avidin/biotin blocking for biotin-based detection systems

  • Extended blocking with species-appropriate serum (5-10%)

• Signal amplification:

  • Tyramide signal amplification for low-abundance targets

  • Polymer-based detection systems for IHC applications

  • Extended primary antibody incubation (overnight at 4°C)

• Tissue-specific considerations:

  • Adipose tissue: Extended fixation and permeabilization

  • Brain tissue: Post-fixation processing and specialized buffers

  • Muscle tissue: Extended permeabilization and antigen retrieval

While the search results primarily demonstrate protocols for cell lines, search result indicates that the HIF1AN Polyclonal Antibody (CAB5466) has been validated for IHC-P applications with a recommended dilution of 1:50-1:200, providing a starting point for tissue optimization .

How can HIF1AN antibodies be utilized to study the role of hypoxia in cancer progression?

HIF1AN antibodies provide valuable tools for investigating the complex role of oxygen sensing in cancer biology. Strategic applications include:

• Tumor microenvironment heterogeneity analysis:

  • Use HIF1AN antibodies alongside HIF-1α to map oxygen gradients within tumor sections

  • Correlate HIF1AN and HIF-1α localization with markers of proliferation, apoptosis, and metastatic potential

  • Compare expression patterns between tumor core (typically hypoxic) and periphery (better oxygenated)

• Therapeutic response monitoring:

  • The search results demonstrate that combined treatment with panobinostat (a histone deacetylase inhibitor) and cisplatin affects HIF-1α stability in H23 cells

  • Similar approaches can examine how cancer therapeutics modulate HIF1AN expression and function

  • Track changes in HIF1AN/HIF-1α ratio as a potential biomarker for treatment efficacy

• Metastasis and invasion studies:

  • Compare HIF1AN levels between primary tumors and metastatic lesions

  • Correlate HIF1AN expression with EMT markers and invasion capacity

  • Use knockout/knockdown approaches with validation by HIF1AN antibodies to establish causality

• Cell line models:

  • The search results demonstrate successful detection of HIF1AN in several cancer cell lines including:

    • A172 human glioblastoma

    • HeLa human cervical epithelial carcinoma

    • A549 human lung carcinoma

    • HepG2 human hepatocellular carcinoma

    • MCF7 human breast cancer

  • These validated models provide starting points for cancer-specific investigations

• Drug development applications:

  • Screen compounds for effects on HIF1AN expression and activity

  • Monitor off-target effects of hypoxia-targeting therapies

  • Develop companion diagnostics using HIF1AN as a biomarker

The research described in search result demonstrates that sulforaphane (SFN) inhibits HIF-1α protein accumulation in cancer cell lines (A549, MCF7, 4T1), which suggests potential therapeutic applications targeting the hypoxia pathway . Similar approaches could be developed focusing on HIF1AN as a therapeutic target.

What methodological considerations are important when studying HIF1AN in the context of inflammation and immune response?

The intersection of hypoxia and inflammation represents a critical research area where HIF1AN antibodies can provide valuable insights. Key methodological considerations include:

• Cell type-specific analysis:

  • Different immune cell populations (macrophages, neutrophils, T cells) may express varying levels of HIF1AN

  • Sort cells before Western blot analysis or use multiplex immunofluorescence to distinguish cell-specific expression patterns

  • Consider flow cytometry with intracellular staining for high-throughput analysis across multiple immune populations

• Stimulation protocols:

  • The search results show that IL-1β (1 ng/ml, 4 hours) treatment affects HIF-1α expression in A549 cells

  • Design time-course experiments to capture both acute and chronic inflammatory effects on HIF1AN

  • Compare inflammatory stimuli (cytokines, PAMPs) with hypoxic stimuli to distinguish pathway-specific effects

• HIF1AN-inflammation crosstalk analysis:

  • Examine HIF1AN expression in relation to NF-κB pathway activation

  • Investigate the relationship between HIF1AN and inflammatory mediators like PGE2

  • The search results indicate that SFN suppresses the HIF-1-mPGES-PGE2 axis, suggesting complex regulation involving HIF1AN

• In vivo inflammation models:

  • Use validated HIF1AN antibodies for tissue analysis in models of inflammatory disease

  • Compare acute vs. chronic inflammation models to assess temporal regulation

  • Consider tissue-specific differences in HIF1AN regulation during inflammation

• Technical considerations for inflammatory samples:

  • Protease inhibitor cocktails are essential when processing inflammatory tissues with high protease content

  • Consider fixing samples immediately to prevent ex vivo hypoxia from altering HIF1AN/HIF-1α expression

  • Include phosphatase inhibitors to preserve post-translational modifications

• Therapeutic implications:

  • Test anti-inflammatory compounds for effects on HIF1AN/HIF-1α pathway

  • Investigate whether HIF1AN modulation could represent a novel anti-inflammatory strategy

The research described in search result showing that IL-1β treatment affects HIF-1α expression and that SFN suppresses the HIF-1-mPGES-PGE2 axis provides a foundation for further investigating this interplay .

How can novel imaging techniques enhance our understanding of HIF1AN spatial dynamics?

Cutting-edge imaging approaches offer new opportunities to study HIF1AN's spatial organization and temporal dynamics at unprecedented resolution:

• Super-resolution microscopy applications:

  • Stimulated emission depletion (STED) microscopy can resolve HIF1AN localization below the diffraction limit (~20-30 nm resolution)

  • Stochastic optical reconstruction microscopy (STORM) enables single-molecule localization of HIF1AN

  • These techniques could reveal previously undetectable subcellular compartmentalization of HIF1AN

• Live-cell imaging strategies:

  • CRISPR-mediated endogenous tagging of HIF1AN with fluorescent proteins

  • Optically-highlighted HIF1AN to track protein movement between compartments

  • Fluorescence recovery after photobleaching (FRAP) to assess HIF1AN mobility under different oxygen tensions

• Correlative light and electron microscopy (CLEM):

  • Combine immunofluorescence detection of HIF1AN with ultrastructural context

  • Precisely locate HIF1AN within organelles and membrane structures at nanometer resolution

  • Particularly valuable for studying HIF1AN's association with mitochondria and other membranous structures

• Tissue clearing and light-sheet microscopy:

  • 3D visualization of HIF1AN distribution throughout intact tissues and organoids

  • Spatial mapping of oxygen gradients in relation to HIF1AN activity

  • Whole-organ analysis of HIF1AN expression in development and disease

• Proximity labeling approaches:

  • BioID or APEX2 fusion proteins to identify proteins in proximity to HIF1AN

  • Spatial mapping of HIF1AN's interactome under normoxic versus hypoxic conditions

  • Integration with mass spectrometry for systematic interaction profiling

• Multiplexed imaging technology:

  • Cyclic immunofluorescence (CycIF) or imaging mass cytometry to simultaneously visualize HIF1AN with dozens of other proteins

  • Mass spectrometry imaging for label-free detection of HIF1AN and metabolic changes

The conventional ICC methods described in the search results provide foundational protocols that can be adapted for these advanced imaging modalities. For example, the successful detection of HIF1AN in A172 human glioblastoma cells and C2C12 mouse myoblast cells using Mouse Anti-Human/Mouse FIH-1/HIF-1AN Monoclonal Antibody (3-25 μg/mL) established parameters that can be optimized for super-resolution applications .